|
| Stage of development | Targeted disease | Sponsor/company | Therapy |
|
Phases I and II
NCT02563782, NCT01469832, NCT01344993, NCT01345006 | AMD, SMD | Astellas Institute for Regenerative Medicine | Allogenic hESC-RPE, cell suspension injection |
Phase I/II
NCT01674829 | Dry AMD | CHA Biotech Co. Ltd. | Allogeneic hESC-RPE, cell suspension injection |
Phase I/II
NCT02286089 | Dry AMD, GA | Cell Cure Neurosciences Ltd. | Allogeneic hESC-RPE, cell suspension injection |
Phase I/II
NCT02590692 | Dry AMD, GA | Regenerative Patch Technologies LLC | Allogeneic hESC-RPE, epithelium on a parylene membrane |
| Phase I/II | AMD | RIKEN Centre for Developmental Biology | Autologous and allogenic hiPSC-RPE, epithelium without substrate |
Phase I
NCT01691261 | Wet AMD | Pfizer/London Project to Cure Blindness | Allogenic hESC-RPE, epithelium on polyester membrane |
| cGMP optimization | AMD, SMD, RP | Cellular Dynamics International/NEI | Autologous hiPSC-RPE, epithelium on biodegradable scaffold |
| Phase I/II | RP with genetic defects in LRAT, MERTK, RPE65 | I-Stem/Institut de la Vision | Allogeneic hESC-RPE, epithelium on amniotic membrane |
| Preclinical | AMD, best disease, LCA | HMC, Israel | Allogeneic hESC-RPE, cell suspension injection |
Phase I/II
NCT03046407, NCT02749734, NCT02755428 | Dry AMD, SMD | Chinese Academy of Sciences, Southwest Hospital, China | Allogeneic hESC-RPE |
Phase I/II
NCT02903576 | Dry AMD, wet AMD, SMD | Federal University of São Paulo | Allogeneic hESC-RPE as cell suspension versus as a sheet on a polymeric substrate |
|
